Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915444 · ClinicalTrials.gov registry record · Phase 2
Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
A Phase 2 study of Pancreatic Ductal Adenocarcinoma, sponsored by HonorHealth Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 4
- Study locations
NCT03915444 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by HonorHealth Research Institute. The registered enrollment target is 42 participants, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03915444, a Phase 2 study of Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by HonorHealth Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Conditions Studied
Interventions
- DRUG nab-Paclitaxel + Cisplatin + Gemcitabine
Study Locations (4)
Arizona
- HonorHealth Research Institute - Scottsdale
Florida
- University of Miami - Miami
Louisiana
- Ochsner Clinic Foundation - New Orleans
Wisconsin
- Froedtert & Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2023-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03915444
The ClinicalTrials.gov registry entry for NCT03915444 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (93% lower). The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which nab-Paclitaxel + Cisplatin + Gemcitabine is the first listed.
NCT03915444 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT03915444 about?
NCT03915444 is a clinical study titled "Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma". This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
What is the current status of trial NCT03915444?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2019-07-15. Estimated completion is 2023-07-31.
What conditions does trial NCT03915444 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT03915444?
The interventions under investigation include: nab-Paclitaxel + Cisplatin + Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT03915444?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03915444 being conducted?
This trial has 4 study locations across Arizona, Florida, Louisiana, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
-
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.